LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
LUMIGAN® 0.01% was approved by the U.S. Food and Drug Administration (FDA) in 2010 for the treatment of high eye pressure, also called intraocular pressure (IOP), in people with open-angle glaucoma or ocular hypertension.
Important Safety Information
LUMIGAN® (bimatoprost ophthalmic solution) 0.01% has been reported to cause darkening (pigmentation) of eye color, eyelid skin and eyelashes, as well as increased growth of eyelashes. Pigmentation changes can increase as long as LUMIGAN® 0.01% is used. After stopping LUMIGAN® 0.01%, darkening of eye color is likely to be permanent while darkening of the eyelid skin and eyelash changes may be reversible. The effects of increased darkening beyond 5 years are not known.
When only one eye is treated, there is a possibility of eyelash changes in the eye treated with LUMIGAN® 0.01%. These changes may result in differences between the eyes in eyelash length, thickness, darkness, number of eyelashes and/or direction of eyelash growth. These changes are usually reversible upon stopping LUMIGAN® 0.01% therapy.
Avoid allowing the tip of the dispensing bottle to touch the eye, anything around the eye, fingers, or any other surface in order to avoid contamination by common bacteria known to cause eye infections. Serious damage to the eye and loss of vision may result from using contaminated solutions.
If you have eye surgery or develop any eye reactions (such as trauma or infection), immediately consult with your physician about continuing the use of LUMIGAN® 0.01%.
If you wear contact lenses, remove them before using LUMIGAN® 0.01%. Then wait 15 minutes after using LUMIGAN® 0.01% before you put your contacts back into your eyes.
The most common side effects are eye redness, growth of eyelashes, and itchy eyes.
For more information about LUMIGAN® (bimatoprost ophthalmic solution) 0.01%, please refer to the full prescribing information and the product website at www.lumigan.com.